Amikacin: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Amikacin is an [[aminoglycoside]] [[antibiotic]] used to treat different types of [[bacteria|bacterial]] [[infection]]s. Amikacin is most often used for treating severe, hospital-acquired infections with [[multidrug resistance|multidrug resistant]] [[Gram negative]] bacteria such as ''[[Pseudomonas aeruginosa]]'', ''[[Acinetobacter]]'', and ''[[Enterobacter]]''. Amikacin may be combined with a [[beta-lactam]] antibiotic for [[empiric therapy]] for [[febrile neutropenia]]. | Amikacin is an [[aminoglycoside]] [[antibiotic]] used to treat different types of [[bacteria|bacterial]] [[infection]]s. Amikacin is most often used for treating severe, hospital-acquired infections with [[multidrug resistance|multidrug resistant]] [[Gram negative]] bacteria such as ''[[Pseudomonas aeruginosa]]'', ''[[Acinetobacter]]'', and ''[[Enterobacter]]''. Amikacin may be combined with a [[beta-lactam]] antibiotic for [[empiric therapy]] for [[febrile neutropenia]]. | ||
==Category== | ==Category== | ||
Aminoglycoside | Aminoglycoside | ||
| Line 16: | Line 18: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Amikacin description|Description]]''' | '''[[Amikacin description|Description]]''' | ||
'''| [[Amikacin clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Amikacin clinical pharmacology|Clinical Pharmacology]]''' | ||
| Line 29: | Line 32: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Amikacin works by binding to the bacterial [[30S]] [[ribosome|ribosomal]] subunit, causing misreading of [[mRNA]] and leaving the bacterium unable to synthesize [[protein]]s vital to its growth. | Amikacin works by binding to the bacterial [[30S]] [[ribosome|ribosomal]] subunit, causing misreading of [[mRNA]] and leaving the bacterium unable to synthesize [[protein]]s vital to its growth. | ||
Revision as of 17:34, 8 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Amikacin is an aminoglycoside antibiotic used to treat different types of bacterial infections. Amikacin is most often used for treating severe, hospital-acquired infections with multidrug resistant Gram negative bacteria such as Pseudomonas aeruginosa, Acinetobacter, and Enterobacter. Amikacin may be combined with a beta-lactam antibiotic for empiric therapy for febrile neutropenia.
Category
Aminoglycoside
US Brand Names
AMIKACIN SULFATE®, AMIKIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Amikacin works by binding to the bacterial 30S ribosomal subunit, causing misreading of mRNA and leaving the bacterium unable to synthesize proteins vital to its growth.